Premium
Drug Shortages in the United States: A Critical Evaluation of Root Causes and the Need for Action
Author(s) -
Gupta D K,
Huang SM
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.229
Subject(s) - clinical pharmacology , economic shortage , drug , intensive care medicine , medicine , action (physics) , pharmacology , antimicrobial , orphan drug , bioinformatics , biology , linguistics , philosophy , physics , quantum mechanics , government (linguistics) , microbiology and biotechnology
Every day it is easy to find news articles detailing the impact of drug shortages on patients. Where this was once only a concern of patients with rare, orphan diseases, it is now the concern of patients receiving even the most common chemotherapeutic regimens, the most efficacious antimicrobial therapy, or even the most rapid‐acting analgesics, largely as a result of manufacturing quality problems. Unfortunately for many of these patients, there are no efficacious alternatives. Clinical Pharmacology & Therapeutics (2013); 93 2, 133–135. doi: 10.1038/clpt.2012.229